COPD drug launch hits rough waters
MARLBOROUGH, Mass. - The American Association for Respiratory Care asked CMS to clarify its payment policy for Brovana, Sepracor's new long-acting beta-agonist launched April 11. The COPD drug, designed to be taken twice daily, was approved last October but has yet to receive a HCPC code, leaving its viability in the homecare setting in question. Also in April, Dey Laboratories filed suit against Sepracor, alleging patent infringement over the development of Brovana.